{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.6","upperLimit":"81.2","value":"68.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Defined as the time from first response until graft-versus-host disease (GVHD) progression or death. DOR was assessed when all participants who were on the study completed the Day 180 visit.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants began oral administration of ruxolitinib at 5 mg BID; if stable after the first 3 days of treatment, the dose may be increased to 10 mg BID up to approximately 27 months. Participants did receive prednisone daily orally (PO) daily or methylprednisolone daily intravenously( IV) as per protocol.","id":"OG000","title":"Ruxolitinib in Combination With Corticosteroids"}],"paramType":"NUMBER","populationDescription":"Efficacy Evaluable Population included all participants enrolled in this study. Participants who achieved ORR were analyzed for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From Baseline up to 6 months","title":"Percentage of Participants With Six-month Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}